Effectiveness of ustekinumab in postoperative Crohn's disease management: Evidence from a Chinese multicenter cohort

Figure 2 Changes in Rutgeerts score, Harvey-Bradshaw Index, and endoscopic improvement by subgroup following ustekinumab treatment. A and B: Box plots that demonstrated the significant reduction in both endoscopic Rutgeerts scores and clinical Harvey-Bradshaw index (HBI) scores following ustekinumab (UST) treatment. The statistical significance was determined using paired analyses (P < 0.001 for Rutgeerts score; P < 0.001 for HBI score); C: Histogram illustrating endoscopic improvement rates (defined as ≥ 1-point reduction in the Rutgeerts score) across key patient subgroups, including the treatment line (i.e., first-line vs second-line UST) and disease characteristics based on the Montreal classification. The overall endoscopic improvement rate was 81.7% (58/71 patients). Together, these panels indicate substantial improvement in endoscopic and clinical disease activity following UST treatment, with differential responses observed across the patient subgroups. UST: Ustekinumab.